

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 498/04, A61K 31/535, A61P 15/18, 35/00 // (C07D 498/04, 265:00, 221:00)		A1	(11) International Publication Number: WO 00/66592
			(43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/US00/11836		TEREFEENKO, Eugene, A. [US/US]; 266 Live Oak Drive, Quakertown, PA 18951 (US). VIET, Andrew, Q. [US/US]; Apt. L-200, 250 Beverly Boulevard, Upper Darby, PA 19082 (US). ZHI, Lin [CN/US]; 7794 Roan Road, San Diego, CA 92129 (US). JONES, Todd, K. [US/US]; 546 Marview Drive, Solana Beach, CA 92075 (US). TEGLEY, Christopher, M. [US/US]; 478 Thunderhead Street, Thousand Oaks, CA 91360 (US). WROBEL, Jay, E. [US/US]; 15 Rosetree Lane, Lawrenceville, NJ 08648 (US). EDWARDS, James, P. [US/US]; 8723 Hesby Court, San Diego, CA 92129 (US). (74) Agents: KODROFF, Cathy, A. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(22) International Filing Date: 1 May 2000 (01.05.00)			
(30) Priority Data: 60/183,037 4 May 1999 (04.05.99) US 09/552,356 19 April 2000 (19.04.00) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US Not furnished (CON) Filed on 19 April 2000 (19.04.00)			
(71) Applicants (for all designated States except US): AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07840 (US). LIGAND PHARMACEUTICALS, INC. [US/US]; 10275 Science Center Drive, San Diego, CA 92121 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): ZHANG, Puwen [CN/US]; 7004 Oriole Court, Audubon, PA 19403 (US). SANTILLI, Arthur, A. [US/US]; 1737 Sue Ellen Drive, Havertown, PA 19083 (US). FENSOME, Andrew [GB/US]; 779 Trephanny Lane, Wayne, PA 19087 (US).			
(54) Title: CYCLIC UREA AND CYCLIC AMIDE DERIVATIVES			
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <p>(I)</p> </div> <div style="text-align: center;"> <p>(a)</p> </div> </div>			
(57) Abstract			
<p>This invention provides compounds of formula (I) wherein: A, B and D are N or CH, with the proviso that A, B and D can not all be CH; R¹ and R² are independent substituents selected from H, COR^A, NR^BCOR^A, or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or groups; or R¹ and R² are fused to form an optionally substituted 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic ring; R^A is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R^B is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl; R³ is H, OH, NH₂, or optionally substituted alkyl, or alkenyl, or COR^C; R^C is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R⁴ is a substituted benzene ring or a five or six membered ring with 1, 2 or 3 heteroatoms from the group including O, S, SO, SO₂ or NR⁵; R^F is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R^G is H, alkyl, or substituted alkyl; R⁵ is H or alkyl; Q is O, S, NR⁶, or CR⁷R⁸; R⁶ is CN, SO₂CF₃, or optionally substituted alkyl, cycloalkyl, aryl, or heterocyclic; R⁷ and R⁸ are H, NO₂, CN CO₂R⁹, or optionally substituted alkyl, cycloalkyl, aryl, or heterocyclic; R⁹ is C₁ to C₃ alkyl; or CR⁷R⁸ form a six membered ring of structure (a); W is O or a chemical bond; or a pharmaceutically acceptable salt thereof, as well as their use and pharmaceutical compositions as agonists and antagonists of the progesterone receptor.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CP	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CYCLIC UREA AND CYCLIC AMIDE DERIVATIVES

Field of the Invention

This invention relates to compounds which are agonists and antagonists of the
5 progesterone receptor, their preparation and utility.

Background of the Invention

Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand dependent transcription factors" (R. M. Evans, *Science*, **240**, 889,
10 1988). The steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR).

The natural hormone, or ligand, for the PR is the steroid progesterone, but synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have
15 been made which also serve as ligands. Once a ligand is present in the fluid surrounding a cell, it passes through the membrane *via* passive diffusion, and binds to the IR to create a receptor/ligand complex. This complex binds to specific gene promoters present in the cell's DNA. Once bound to the DNA the complex modulates the production of mRNA and protein encoded by that gene.

20 A compound that binds to an IR and mimics the action of the natural hormone is termed an agonist, whilst a compound that inhibits the effect of the hormone is an antagonist.

PR agonists (natural and synthetic) are known to play an important role in the health of women. PR agonists are used in birth control formulations, typically in the
25 presence of an ER agonist. ER agonists are used to treat the symptoms of menopause, but have been associated with a proliferative effect on the uterus that can lead to an increased risk of uterine cancers. Co-administration of a PR agonist reduces or ablates that risk.

- 2 -

PR antagonists may also be used in contraception. In this context they may be administered alone (Ulmann, et al, *Ann. N.Y. Acad. Sci.*, **261**, 248, 1995), in combination with a PR agonist (Kekkonen, et al, *Fertility and Sterility*, **60**, 610, 1993) or in combination with a partial ER antagonist such as tamoxifen (WO 96/19997 A1, July 4, 1996).

PR antagonists may also be useful for the treatment of hormone dependent breast cancers (Horwitz, et al, *Horm. Cancer*, 283, pub: Birkhaeuser, Boston, Mass., ed. Vedeckis) as well as uterine and ovarian cancers. PR antagonists may also be useful for the treatment of non-malignant chronic conditions such as fibroids (Murphy, et al, *J. Clin. Endo. Metab.*, **76**, 513, 1993) and endometriosis (Kettel, et al, *Fertility and Sterility*, **56**, 402, 1991).


PR antagonists may also be useful in hormone replacement therapy for post menopausal patients in combination with a partial ER antagonist such as tamoxifen (US 5719136).

PR antagonists, such as mifepristone and onapristone, have been shown to be effective in a model of hormone dependent prostate cancer, which may indicate their utility in the treatment of this condition in men (Michna, et al, *Ann. N.Y. Acad. Sci.*, **761**, 224, 1995).


The compounds of this invention have been shown to act as competitive inhibitors of progesterone binding to the PR and act as agonists and/or antagonists in functional models, either/or *in-vitro* and *in-vivo*. These compounds may be used for contraception, in the treatment of fibroids, endometriosis, breast, uterine, ovarian and prostate cancer, and post menopausal hormone replacement therapy.

Jones, et al, (U.S. Patent No. 5,688,810) describe the PR antagonist dihydroquinoline **1**.


- 3 -

**1**

Jones, *et al*, described the enol ether **2** (U.S. Patent No. 5,693,646) as a PR ligand.


**2**

Jones, *et al*, described compound **3** (U.S. Patent No. 5,696,127) as a PR ligand.


**3**

- 4 -


Zhi, *et al.*, described lactones 4, 5 and 6 as PR antagonists (J. Med. Chem., 41, 291, 1998).



Zhi, *et al.*, described the ether 7 as a PR antagonist (J. Med. Chem., 41, 291, 1998).




Combs, *et al.*, disclosed the amide 8 as a ligand for the PR (J. Med. Chem., 38, 4880, 1995).




- 5 -

Perlman, *et al.*, described the vitamin D analog **9** as a PR ligand (*Tet. Letters*, **35**, 2295, 1994).

**9**

5


Hamann, *et al.*, described the PR antagonist **10** (*Ann. N.Y. Acad. Sci.*, **761**, 383, 1995).

**10**

10


Chen, *et al.*, described the PR antagonist **11** (Chen, *et al.*, POI-37, 16th Int. Cong. Het. Chem., Montana, 1997).

- 6 -



11




Kurihari, *et. al.*, described the PR ligand 12 (*J. Antibiotics*, **50**, 360, 1997).



12



5
10 The patent by Christ et al. (WO 9814436) claims cyclo amide such as compound **A** as inhibitors of HIV reverse transcriptase. Other prior art includes pyridazine cyclo amide such as compound **B** by Turck et al. (*Tetrahedron*, **49**(3), 599-606 (1993).) and compound such as **C** by Canonne et al. (*J. heterocyclic Chem.* **26**, 113(1989).). No activity data were reported in Turck's and Canonne' publications.

- 7 -



Regarding cyclic amides, Singh et al. and Kumar et al. (Singh et al. *J. Med. Chem.* **37**(2), 248-254(1994); Kumar et al. *J. Org. Chem.* **57**(25), 6995-6998(1992).)

5 disclose compounds such as D and E claimed as cAMP PDE III inhibitors.




Description of the invention

10

This invention provides compounds of Formula I:

- 8 -



wherein:

A, B and D are N or CH, with the proviso that A, B and D can not all be CH;

R¹ and R² are independent substituents selected from H, C₁ to C₆ alkyl,
 5 substituted C₁ to C₆ alkyl, C₂ to C₆ alkenyl, substituted C₂ to C₆ alkenyl, C₂ to C₆
 alkynyl, substituted C₂ to C₆ alkynyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈
 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A,
 NR^BCOR^A;

or R¹ and R² are fused to form a spirocyclic ring selected from a), b) or c),
 10 each spirocyclic ring optionally substituted by from 1 to 3 C₁-C₃ alkyl groups:

- a) a 3 to 8 membered spirocyclic alkyl ring;
- b) a 3 to 8 membered spirocyclic alkenyl ring; or
- c) an optionally substituted 3 to 8 membered heterocyclic ring

containing one to three heteroatoms from the group including O, S and N; the
 15 spirocyclic rings of a), b) and c) being optionally substituted by from 1 to 4 groups
 selected from fluorine, C₁ to C₆ alkyl, C₁ to C₆ alkoxy, C₁ to C₆ thioalkyl, -CF₃, -OH, -
 CN, NH₂, -NH(C₁ to C₆ alkyl), or -N(C₁ to C₆ alkyl)₂;

R^A is H, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, aryl, substituted aryl, C₁ to
 C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, or substituted C₁ to C₃
 20 aminoalkyl;


R^B is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl;

R³ is H, OH, NH₂, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₆ alkenyl,
 substituted C₁ to C₆ alkenyl, or COR^C;

- 9 -

R^C is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^4 is a trisubstituted benzene ring containing the substituents X, Y and Z as
5 shown below:



X is taken from the group including halogen, CN, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 thioalkoxy, substituted C_1 to C_3 thioalkoxy, amino, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5 or 6 membered heterocyclic ring
10 containing 1 to 3 heteroatoms, COR^D , $OCOR^D$, or $NR^E COR^D$;

R^D is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

15 R^E is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

Y and Z are independent substituents taken from the group including H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_3 alkyl, or C_1 to C_3 thioalkoxy;

or

R^4 is a five or six membered ring with 1, 2, or 3 heteroatoms from the group
20 including O, S, SO, SO_2 or NR^5 and containing one or two independent substituents from the group including H, halogen, CN, NO_2 and C_1 to C_3 alkyl, C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, COR^F , or $NR^G COR^F$;

R^F is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to
25 C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^G is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

- 10 -

R^5 is H or C_1 to C_3 alkyl;


Q is O, S, NR^6 , or CR^7R^8 ;

R_6 is from the group including CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl,
 5 C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic,
 substituted heterocyclic, or SO_2CF_3 ;

R^7 and R^8 are independent substituents from the group including H, C_1 to C_6
 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl,
 aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , CN, or CO_2R^9 ;

10 R^9 is C_1 to C_3 alkyl;


or CR^7R^8 form a six membered ring of the structure below:



W is O or a chemical bond.


15

When W is a chemical bond, it is understood that Formula I exists as:



Preferred compounds are those of Formula I

- 11 -



I

wherein:

A, B and D are N or CH, with the proviso that A, B and D can not all be CH;

5 R¹ is H, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A, or NR^BCOR^A;

 R² is H, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₂ to C₆ alkenyl, substituted C₂ to C₆ alkenyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A, or NR^BCOR^A;

10 or

 R¹ and R² are fused to form the optionally substituted 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings described above;

 R^A is H, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, aryl, substituted aryl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, or substituted C₁ to C₃ aminoalkyl;


 R^B is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl;

 R³ is H, OH, NH₂, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₆ alkenyl, substituted C₁ to C₆ alkenyl, or COR^C;

20 R^C is H, C₁ to C₄ alkyl, substituted C₁ to C₄ alkyl, aryl, substituted aryl, C₁ to C₄ alkoxy, substituted C₁ to C₄ alkoxy, C₁ to C₄ aminoalkyl, or substituted C₁ to C₄ aminoalkyl;

 R⁴ is a trisubstituted benzene ring containing the substituents X, Y and Z as shown below:

- 12 -



X is selected from halogen, CN, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ thioalkoxy, substituted C₁ to C₃ thioalkoxy, C₁ to C₃ aminoalkyl, substituted C₁ to C₃ aminoalkyl, NO₂, C₁ to C₃ perfluoroalkyl, a 5 membered heterocyclic ring containing 1 to 3 heteroatoms, COR^D, OCOR^D, or NR^ECOR^D;

R^D is H, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, aryl, substituted aryl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, or substituted C₁ to C₃ aminoalkyl;

10 R^E is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl;

Y and Z are independent substituents selected from H, halogen, CN, NO₂, C₁ to C₃ alkoxy, C₁ to C₃ alkyl, or C₁ to C₃ thioalkoxy;

or

15 R⁵ is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO₂ or NR⁵ and containing one or two independent substituents from the group including H, halogen, CN, NO₂ and C₁ to C₃ alkyl, or C₁ to C₃ alkoxy;

R⁵ is H or C₁ to C₃ alkyl;

Q is O, S, NR⁶, or CR⁷R⁸;


20 R₆ is selected from CN, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO₂CF₃;

R⁷ and R⁸ are independent substituents selected from H, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO₂, or CN CO₂R⁹;

25 R⁹ is C₁ to C₃ alkyl;

or CR⁷R⁸ form a six membered ring of the structure below:


- 13 -



W is O or a chemical bond;

or a pharmaceutically acceptable salt thereof.

5 Still, more preferred compounds are those of Formula I



I

wherein:


A, B and D are N or CH, with the proviso that A, B and D cannot all be CH;

10 $R^1 = R^2$ and are selected from the group of C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, or spirocyclic alkyl constructed by fusing R^1 and R^2 to form a 3 to 6 membered spirocyclic ring;

R^3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, or COR^C ;

R^C is H, C_1 to C_4 alkyl, or C_1 to C_4 alkoxy;

15 R^4 is a disubstituted benzene ring containing the substituents X, and Y as shown below:




- 14 -

X is selected from the group of halogen, CN, C₁ to C₃ alkoxy, C₁ to C₃ alkyl, NO₂, C₁ to C₃ perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C₁ to C₃ thioalkoxy;

Y is a substituent on the 4' or 5' position from the group including H, halogen, CN, NO₂, C₁ to C₃ alkoxy, C₁ to C₄ alkyl, or C₁ to C₃ thioalkoxy;

or

R⁴ is a five membered ring with the structure:



U is O, S, or NR⁵;


R⁵ is H, or C₁ to C₃ alkyl, or C₁ to C₄ CO₂alkyl;

X' is selected from halogen, CN, NO₂, C₁ to C₃ alkyl, or C₁ to C₃ alkoxy;

Y' is selected from H and C₁ to C₄ alkyl;

or

R⁴ is a six membered ring with the structure:



X¹ is N or CX²;

X² is halogen, CN or NO₂;

Q is O, S, NR⁶, or CR⁷R⁸;


R₆ is selected from CN, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO₂CF₃;

- 15 -

R^7 and R^8 are independent substituents selected from H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , CN, or CO_2R^9 ;

R^9 is C_1 to C_3 alkyl;


5 or CR^7R^8 form a six membered ring of the structure below:



or a pharmaceutically acceptable salt thereof.

Further preferred compounds include those of Formula I:

10



I

wherein:

A, B and D are N or CH, with the proviso that A, B and D can not all be CH;

$R^1 = R^2$ and are selected from CH_3 and spirocyclic alkyl constructed by fusing


15 R^1 and R^2 to form a 6 membered spirocyclic ring;

R^3 is H, OH, NH_2 , CH_3 , substituted methyl, or COR^C ;

R^C is H, C_1 to C_3 alkyl, or C_1 to C_4 alkoxy;

R^4 is a disubstituted benzene ring containing the substituents X and Y as shown below:

- 16 -




X is halogen, CN, methoxy, NO₂, or 2-thiazole;

Y is a substituent on the 4' or 5' position selected from H and F;

5 or

R⁴ is a five membered ring of the structure:



U is O, S, or NH;

X' is halogen, CN, or NO₂;

10

Y' is H or C₁ to C₄ alkyl;

Q is O, S, NR⁶, or CR⁷R⁸;


R₆ is CN, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO₂CF₃;

15

R⁷ and R⁸ are independent substituents selected from H, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO₂, or CN CO₂R⁹;

R⁹ is C₁ to C₃ alkyl;

or CR⁷R⁸ form a six membered ring of the structure:



20

- 17 -

W is O or a chemical bond;

or a pharmaceutically acceptable salt thereof.

Each of the generic and subgeneric groups of compounds described above, as well as the methods of treatment and pharmaceutical compositions utilizing them, may be divided into two further subgeneric groups, one in which Q is oxygen and another in which Q is sulfur or NR⁶ or CR⁷R⁸.

The compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry in Formula I, the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.

The term "alkyl" is used herein to refer to both straight- and branched-chain saturated aliphatic hydrocarbon groups having one to eight carbon atoms, preferably one to six carbon atoms; "alkenyl" is intended to include both straight- and branched-chain alkyl group with at least one carbon-carbon double bond and two to eight carbon atoms, preferably two to six carbon atoms; "alkynyl" group is intended to cover both straight- and branched-chain alkyl group with at least one carbon-carbon triple bond and two to eight carbon atoms, preferably two to six carbon atoms.

The terms "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" refer to alkyl, alkenyl, and alkynyl as just described having one or more substituents from the group including halogen, CN, OH, NO₂, amino, aryl, heterocyclic, substituted aryl, substituted heterocyclic, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, arylthio. These substituents may be attached to any carbon of alkyl, alkenyl, or alkynyl group provided that the attachment constitutes a stable chemical moiety.

The term "aryl" is used herein to refer to an aromatic system which may be a single ring or multiple aromatic rings fused or linked together as such that at least one part of the fused or linked rings forms the conjugated aromatic system. The aryl groups include but not limited to phenyl, naphthyl, biphenyl, anthryl, tetrahydronaphthyl, phenanthryl.

The term "substituted aryl" refers to aryl as just defined having one to four substituents from the group including halogen, CN, OH, NO₂, amino, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio.

The term "heterocyclic" is used herein to describe a stable 4- to 7-membered monocyclic or a stable multicyclic heterocyclic ring which is saturated, partially unsaturated, or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group including N, O, and S atoms. The N and S atoms may be oxidized. The heterocyclic ring also includes any multicyclic ring in which any of above defined heterocyclic rings is fused to an aryl ring. The heterocyclic ring may be attached at any heteroatom or carbon atom provided the resultant structure is chemically stable. Such heterocyclic groups include, for example, tetrahydrofuran, piperidinyl, piperazinyl, 2-oxopiperidinyl, azepinyl, pyrrolidinyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, morpholinyl, indolyl, quinolinyl, thienyl, furyl, benzofuranyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, and isoquinolinyl.

The term "substituted heterocyclic" is used herein to describe the heterocyclic just defined having one to four substituents selected from the group which includes halogen, CN, OH, NO₂, amino, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio. The term "alkoxy" is used herein to refer to the OR group, where R is alkyl or substituted alkyl. The term "aryloxy" is used herein to refer to the OR group, where R is aryl or substituted aryl. The term "alkylcarbonyl" is used herein to refer to the RCO group, where R is alkyl or substituted alkyl. The term

- 19 -

“alkylcarboxy” is used herein to refer to the COOR group, where R is alkyl or substituted alkyl. The term “aminoalkyl” refers to both secondary and tertiary amines wherein the alkyl or substituted alkyl groups containing one to eight carbon atoms, which may be either same or different and the point of attachment is on the nitrogen atom. “Halogen” refers to Cl, Br, F, or I.

The compounds of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases. These salts include, but are not limited to, the following salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and maleic acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium in the form of esters, carbamates and other conventional “pro-drug” forms, which, when administered in such form, convert to the active moiety *in vivo*.

This invention includes pharmaceutical compositions and treatments which comprise administering to a mammal a pharmaceutically effective amount of one or more compounds as described above wherein Q is oxygen as antagonists of the progesterone receptor. The invention further provides comparable methods and compositions which utilize one or more compounds herein wherein Q is S, NR⁶, or CR⁷R⁸ as agonists of the progesterone receptor.

The progesterone receptor antagonists of this invention, used alone or in combination, can be utilized in methods of contraception and the treatment and/or prevention of benign and malignant neoplastic disease. Specific uses of the compounds and pharmaceutical compositions of invention include the treatment and/or prevention of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors. Additional uses of the present progesterone receptor antagonists include the synchronization of the estrus in livestock.

- 20 -

The progesterone receptor agonists of this invention, used alone or in combination, can be utilized in methods of contraception and the treatment and/or prevention of dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate. Additional uses of the invention include stimulation of food intake.

When the compounds are employed for the above utilities, they may be combined with one or more pharmaceutically acceptable carriers or excipients, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in a sustained release form. For most large mammals, the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

- 21 -

These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

- 10 The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

15 These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.


- 20 The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringe ability exists. It must be stable under conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.
- 25

The compounds of this invention can be prepared following the Schemes illustrated below:

As demonstrated in Scheme I, the compounds of this invention are generally prepared by employing the suitable coupling reaction as a final step. An appropriately substituted ortho-amino acid or its derivatives such as ethyl ester (X = Br, I, Cl, or a latent coupling precursor such as alkoxy group which can be converted into OTf group suitable in the coupling reaction) is treated with a suitable organo metallic reagent, e.g. Grignard reagent, in appropriate nonprotic solvents which include but not limited to THF or ether to give ortho-amino carbinol 2 under an inert atmosphere such as argon or nitrogen at -78 °C to room temperature. Ring closure of carbinol 2 to yield oxazin-2-ones 3 is commonly effected by a condensing agent such as carbonyldiimidazole, phosgene, dimethylcarbonate, or diethylcarbonate in a suitable nonprotic solvent such as THF at temperatures ranging from room temperature to 65 °C. The arylation of oxazin-2-ones 3 to yield 4 can be effected by various coupling reactions including Suzuki, Stille reactions etc.. These reactions are commonly performed in the presence of transition metallic catalyst, e.g., palladium or nickel complex often with phosphino ligands, e.g., Ph_3P , 1,1'-bis(diphenylphosphino)ferrocene, 1,2-bis(diphenylphosphino)ethane or palladium salt such as palladium acetate. Under this catalytic condition, an appropriately substituted nucleophilic reagent, e.g., aryl boronic acid, arylstannane, or aryl zinc compound, is coupled with oxazinones 3 to give compounds 4. If a base is needed in the reaction, the commonly used bases include but not limited to sodium bicarbonate, sodium carbonate, potassium phosphate, barium carbonate, potassium acetate, or cesium fluoride. The most commonly used solvents in these reactions include benzene, DMF, isopropanol, ethanol, DME, ether, acetone or a mixture of any one of these solvent and water. The coupling reaction is generally executed under an inert atmosphere such as nitrogen or argon at temperatures ranging from room temperature to 95 °C. Oxazinones 3 can be converted into a nucleophile such as boronic acid which can be coupled with an appropriate electrophile, e.g., aryl

- 23 -

bromide or aryl iodide, to yield **6** employing the coupling reaction condition as described above.



The transformation of **3** into **5** can be effected by treating **3** with an organo metallic reagent, e.g., *n*-BuLi, in a nonprotic solvent such as THF or ether followed by quenching the reaction solution with a suitable electrophile such as trimethyl borate, triisopropyl borate, bishexalkyl tin reagent, or zinc chloride at temperatures ranging from -78 °C to room temperature under an inert atmosphere such as argon or nitrogen.


- 24 -

Conversion of carbamate 6 to thiocarbamate 7 can be readily effected by treatment of 6 with a suitable sulfur reagent such as P_2S_5 or Lawesson's reagent in a suitable nonprotic solvent such as toluene, chlorobenzene, benzene, or xylene under an inert atmosphere such as argon or nitrogen at the temperature of boiling solvent.

5 Scheme II describes the procedures to prepare oxazinones bearing two different substituents at position-4. The Weinreb amide 9 can be prepared from an appropriately substituted isatoic anhydride when treated with *N*-, *O*-dimethylhydroxylamine hydrochloride salt in a protic solvent such as ethanol or isopropanol at reflux under an inert atmosphere such as argon or nitrogen. Coupling of amide 9 with an aryl
10 electrophile such as aryl boronic acid or arylstannane to give 10 can be effected by employing a typical coupling reaction such as Suzuki, Stille coupling procedure in a similar fashion as described for the preparation of oxazinones 4. Treatment of Weinreb amide 10 with organo metallic compounds, e.g., alkyllithium, alkynyllithium, aryllithium, or their Grignard counterpart in a nonprotic solvent such as THF or ether
15 under an inert atmosphere such as argon or nitrogen at -78° to room temperature affords amino ketone 11. Conversion of ketone 11 to carbinol 12 can be effected by treatment of 10 with an organo metallic reagent such as alkyl, alkynyl, or aryl Grignard compound in a nonprotic solvent such as THF or ether under an inert atmosphere such as argon or nitrogen at -78°C to room temperature. Conversion of ketone 11 to
20 carbinol 12 can also be effected by reduction of ketone group of 11 to the carbinol moiety of 12 using an appropriate reducing reagent such as lithium aluminum hydride, sodium borohydride in a suitable solvent such as THF, ether, or anhydrous alcohol under an inert atmosphere in the temperature ranging from 0°C to the boiling point of the solvent. Ring closure of carbinol 12 to produce the compounds of this invention,
25 13, can be accomplished with condensing agents such as carbonyldiimidazole, phosgene, dimethylcarbonate, or diethylcarbonate in a suitable nonprotic solvent such as THF at temperatures ranging from room temperature to 65°C . Conversion of carbamate 13 to thiocarbamate 14 can be readily effected by treatment of 13 with a suitable sulfur reagent such as P_2S_5 or Lawesson's reagent in a suitable nonprotic


solvent such as toluene, chlorobenzene, benzene, or xylene under an inert atmosphere such as argon or nitrogen at the temperature of boiling solvent.

Scheme II



- 26 -

Alternatively, ortho-amino ketone **11** can be prepared by treatment of ortho-amino nitrile **16** with an organo metallic compound such as organo lithium reagent or Grignard reagent in a suitable solvent such as THF or ether under an inert atmosphere such as argon or nitrogen at temperatures ranging from -78 °C to room temperature as illustrated in Scheme III. Nitrile **16** can be readily prepared from an appropriately substituted nitrile such as bromobenzonitrile **15** using a suitable coupling reaction such as Stille or Suzuki protocol carried out in a similar fashion as described for the preparation of the Weinreb amide **10**.



10

The following non-limiting examples illustrate the compounds of the invention.

15

EXAMPLE 1

2-Amino-5-bromo-3-pyridine carboxylic acid

To a solution of 2-amino-nicotinic acid (10 g, 72.5 mmol) in acetic acid (70 mL) was dropwise added bromine (9.8 mL, 79.8 mmol) at room temperature under nitrogen. Upon completion of the reaction, the solvent was removed *in vacuo*, the

- 27 -

residue triturated with ether and collected on a filter to give 2-amino-5-bromo-3-pyridine carboxylic acid as a yellow solid (15.7 g, 99%): mp 272 °C, (decomposed); ¹H-NMR (DMSO-d₆) δ 8.8-7.8 (bs, 2H), 8.44 (d, 1H, *J* = 2.48 Hz), 8.34 (d, 1H, *J* = 2.48 Hz); MS (EI) *m/z* 216/218 ([*M* +]⁺, 100%)

5

EXAMPLE 2

2-(2-Amino-5-bromo-pyridin-3-yl)-propan-2-ol

To a solution of 2-amino-5-bromo-3-pyridine carboxylic acid (5 g, 23 mmol) in THF (70 mL) at 0 °C was added methyl magnesium bromide (13.7 g, 115 mmol) under nitrogen. After addition, the reaction mixture was heated at 65 °C for 12 hours, cooled to room temperature and quenched with saturated aqueous ammonium chloride. The ethyl acetate was added and organic layer was separated, dried over sodium sulfate and concentrated. The residue was purified *via* flash chromatography to give 2-(2-amino-5-bromo-pyridin-3-yl)-propan-2-ol as a yellow solid (1.2 g, 23%): mp 107-108 °C; ¹H-NMR (DMSO-d₆) δ 7.89 (d, 1H, *J* = 2.3 Hz), 7.40 (d, 1H, *J* = 2.3 Hz), 6.28 (bs, 2H), 5.51 (s, 1H), 1.4 (s, 6H); MS (APCI) *m/z* 231 ([*M* + H]⁺, 100%).

15

EXAMPLE 3

6-Bromo-4,4'-dimethyl-1,4-dihydro-3-oxa-1,8-diaza-naphthalen-2-one

A mixture of 2-(2-amino-5-bromo-pyridin-3-yl)-propan-2-ol (0.86 g, 3.7 mmol) and 1,1'-carbonyldiimidazole (excess) in THF (10 mL) was heated at 35 °C overnight. The reaction solution was cooled to room temperature, poured into ethyl acetate (200 mL), washed with 1 N HCl (2x50 mL), dried over sodium sulfate, and concentrated. The residue was purified by a flash chromatography (silica gel, 25% ethyl acetate/hexane) to afford 6-bromo-4,4'-dimethyl-1,4-dihydro-3-oxa-1,8-diaza-naphthalen-2-one (0.9 g, 94%) as a white solid: mp 251-252 °C; ¹H-NMR (DMSO-d₆) δ 10.9 (s, 1H), 8.32 (d, 1H, *J* = 2.19 Hz), 8.0 (d, 1H, *J* = 2.22 Hz), 1.6 (s, 6H); MS (EI) *m/z* 256 ([*M*]⁺, 80%); Anal. Calc. For C₉H₉BrN₂O₂: C, 42.05, H, 3.53, N, 10.90. Found: C, 42.15, H, 3.65, N, 10.80.

20

25

- 28 -

EXAMPLE 4

6-(3-Chloro-phenyl)-4,4-dimethyl-1,4-dihydro-3-oxa-1,8-diaza-naphthalene-2-one

5 A mixture of 6-bromo-4,4'-dimethyl-1,4-dihydro-3-oxa-1,8-diaza-naphthalen-2-one (0.1 g, 0.39 mmol), 3-chlorophenyl boronic acid (0.075 g, 0.47 mmol), tetrakis(triphenylphosphine)-palladium (0) (0.023 g, 0.02 mmol), and sodium carbonate (0.1 g, 0.94 mmol) in DME (8 mL) and water (5 mL) was subject to a blanket of nitrogen for 15 minutes at 50 °C and then was heated at 85 °C for 30
10 minutes. The reaction was cooled to room temperature and ethyl acetate (100 mL) was added. The organic layer washed with aqueous ammonium chloride (2x50 mL) and with brine (50 mL), dried over magnesium sulfate and concentrated. The product was dissolved in dichloromethane and passed through a plug of magnesol. The solvent was removed and the clear oil obtained triturated with ether (25 mL) to give 6-(3-
15 chloro-phenyl)-4,4-dimethyl-1,4-dihydro-3-oxa-1,8-diaza-naphthalene-2-one as a white solid (0.087 g, 80%): mp 214-215 °C; ¹H-NMR (DMSO-d₆) δ 10.9 (s, 1H), 8.56 (d, 1H, *J* = 2.35 Hz), 8.06 (d, 1H, *J* = 2.35 Hz), 7.86 (t, 1H, *J* = 2.35 Hz), 7.72 (td, 1H, *J* = 9.4, 2.35 Hz), 7.54-7.44 (m, 2H), 1.69 (s, 6H); MS (ESI) *m/z* 289 ([M+H]⁺, 100%); Anal. Calc. For C₁₇H₁₇NO₃: C, 62.40, H, 4.54, N, 9.70. Found:
20 C, 60.53, H, 4.40, N, 9.21.

EXAMPLE 5

6-Chloro-3-nitro-pyridine-2-carbonitrile

25 A mixture of 2, 6-dichloro-3-nitropyridine and cuprous cyanide in 1-methyl-2-pyrrolidinone was quickly heated to 180 °C and maintained at that temperature for 15 minutes with vigorous stirring. The mixture was cooled to -10 °C and the deep brown solution was poured into ice water (3.5 L) and stirred for 30 min. The flocculent brown precipitate was collected and washed with H₂O. After drying for about 1.5 h, the moist solid was extracted with boiling toluene (3x300 mL). The combined toluene

- 29 -

extracts were washed with H₂O, brine, and dried (MgSO₄), concentrated. The crude product was crystallized from EtOAc/hexane to afford the title compound: mp 115-117 °C; ¹H NMR(DMSO-d₆) δ 8.16 (dd, 1H, J = 8.7, 3.0 Hz), 8.82 (d, 1H, J = 9.0 Hz); MS (EI) *m/z* 183/185 (M+H)⁺; Anal. Calc. For C₆H₂ClN₃O₂: C, 39.26, H, 1.10, N, 22.89. Found: C, 39.47, H, 1.38, N, 22.77.

EXAMPLE 6

3-Amino-6-chloro-pyridine-2-carbonitrile

To a solution of 2,6-dichloro-3-nitropyridine (4.8 g, 26.15 mmol) in MeOH (60 mL) and concentrated HCl (25 mL) was slowly added iron powder (5.12g, 91.53 mmol). After the completion of addition, the mixture was refluxed for 45 minutes and poured into 700 mL of H₂O. Filtration of the resulting slurry gave a dull yellow solid. The filtrate was made basic with concentrated NH₄OH, the resulting slurry was filtered and both the solid and the filtrates were extracted with ether. The combined extracts were dried (MgSO₄) and evaporated to give the title compound as a creamy solid (2.8g, 58%): mp 162-165 °C which was used in next step without further purification.

EXAMPLE 7

1-(3-Amino-6-chloro-pyridin-2-yl)-ethanone

To a solution of 3-amino-6-chloro-pyridine-2-carbonitrile (0.75g, 4.88 mmol) in anhydrous THF (25 mL) under nitrogen was added a solution of methylmagnesium bromide (3M in ether, 8.1 mL, 24.3 mmol). The reaction mixture was stirred for 30 minutes and then slowly quenched with H₂O, and treated with 5N HCl solution. The mixture was extracted with ethyl acetate (3x100 mL) and organic extracts were washed with brine, and dried (MgSO₄). After removal of the solvent, the residue was purified by a chromatography using EtOAc/hexane mixture (1:3) as eluent to afford the title compound as a greenish crystalline solid: (0.71g, 85%): mp: 108-110 °C. ¹H

- 30 -

NMR (DMSO- d_6) δ 2.51 (s, 3H), 7.28-7.39 (m, 4H); MS(ESI) m/z 171/173 (M+H)⁺; Anal. Calc. For C₇H₇ClN₂O: C, 49.28, H, 4.14, N, 16.14. Found: C, 49.70, H, 4.03, N, 16.41.

5

EXAMPLE 8**1-(3-Amino-6-chloro-pyridin-2-yl)-propan-2-ol**

To a solution of 1-(3-amino-6-chloro-pyridin-2-yl)-ethanone in anhydrous THF under N₂ was added a solution of methylmagnesium bromide (3N in ether). The resulting reaction mixture was stirred at room temperature for 4 h, then slowly quenched with H₂O, treated with 0.5 N HCl and stirred for 30 minutes, diluted with ethyl acetate, washed with brine, dried (MgSO₄), concentrated, and chromatographed using a mixture of EtOAc/Hexane (3.5: 6.5) to afford the title compound as a white crystals (0.45g, 82%): mp: 118-121 °C. ¹H NMR(DMSO- d_6) δ 1.45(s, 6H), 3.35(s, 1H), 5.51(s, 1H), 5.68(s, 1H), 7.02(s, 1H); MS((+)APCI) m/z 187/189 (M+H)⁺; Anal. Calc. For C₈H₁₁ClN₂O: C, 51.48, H, 5.94, N, 15.01. Found: C, 51.22, H, 5.99, N, 14.47.

10

15

EXAMPLE 9**6-Chloro-4,4-dimethyl-1,4-dihydro-3-oxa-1,5-diaza-naphthalen-2-one**

20

25


To a solution of 1-(3-amino-6-chloro-3-nitro-pyridin-2-yl)-propan-2-ol (0.3g, 1.67 mmol) in anhydrous THF (20 mL) was added a solution of 1,1'-carbonyldiimidazole (0.68g, 4.12 mmol) in anhydrous THF (10 mL). The reaction mixture was heated under reflux for 3 h. The reaction mixture was treated with 0.5N HCl, washed with brine, H₂O, dried (MgSO₄), concentrated and crystallized from EtOAc/hexane to obtain the title compound as a white crystalline solid (0.2g, 56%): mp 175-178 °C. ¹H NMR(DMSO- d_6) δ 1.60 (s, 6H), 7.30 (d, 1H, J = 8.41 Hz), 7.41

- 31 -

(d, 1H, $J = 8.41$ Hz), 10.47 (s, 1H); MS((+)APCI) m/z 213 ($M+H$)⁺; Anal. Calc. For $C_9H_9ClN_2O_2$: C, 50.84, H, 4.27, N, 13.17. Found: C, 50.99, H, 4.28, N, 12.98.

EXAMPLE 10

- 5 The compounds of this invention were tested in the relevant assay as described below and their potency are in the range of 0.01 nM to 5 μ M in the *in vitro* assays and 0.001 to 300 mg/kg in the *in vivo* assays. The selected example is example 4.



Example 4, hPR CV-1, $IC_{50} = 0.8 \mu$ M

10 A. In-vitro biology

- The in-vitro biology is determined by (1) competitive Radioligand Binding: using the A-form of the human progesterone receptor with progesterone as the radioligand; (2) co-transfection assay, which provides functional activity expressed as agonist EC_{50} and Antagonist IC_{50} values; (3) a T47D cell proliferation, which is a further functional assay which also provides agonist and antagonist data; and (4) T47D cell alkaline phosphatase assay, which is a further functional assay which also provides agonist and antagonist data.

- 15 1. hPR Binding assay - This assay is carried out in accordance with: Pathirana, C.; Stein, R.B.; Berger, T.S.; Fenical, W.; Ianiro, T.; Mais, D.E.; Torres, A.; Glodman, M.E., *Nonsteroidal human progesterone receptor modulators from the marine alga cymoplia barbata*, J. Steroid Biochem. Mol. Biol., 1992, **41**, 733-738.

- 32 -

2. PRE-luciferase assay in CV-1 cells

The object of this assay is to determine a compound's progestational or antiprogestational potency based on its effect on PRE-luciferase reporter activity in CV-1 cells co-transfected with human PR and PRE-luciferase plasmids. The materials methods used in the assay are as follows.

a. Medium: The growth medium was as follows:

DMEM (BioWhittaker) containing 10% (v/v) fetal bovine serum (heat inactivated), 0.1 mM MEM non-essential amino acids, 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL). The experimental medium was as follows:

DMEM (BioWhittaker), phenol red-free, containing 10% (v/v) charcoal-stripped fetal bovine serum (heat-inactivated), 0.1 mM MEM non-essential amino acids, 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).

b. Cell culture, transfection, treatment, and luciferase assay

Stock CV-1 cells are maintained in growth medium. Co-transfection is done using 1.2×10^7 cells, 5 mg pLEM plasmid with hPR-B inserted at SphI and BamHI sites, 10 mg pGL3 plasmid with two PREs upstream of the luciferase sequence, and 50 mg sonicated calf thymus DNA as carrier DNA in 250 ml. Electroporation is carried out at 260 V and 1,000 mF in a Biorad Gene Pulser II. After electroporation, cells are resuspended in growth medium and plated in 96-well plate at 40,000 cells/well in 200 μ l. Following overnight incubation, the medium is changed to experimental medium. Cells are then treated with reference or test compounds in experimental medium. Compounds are tested for antiprogestational activity in the presence of 3 nM progesterone. Twenty-four hr. after treatment, the medium is discarded, cells are washed three times with D-PBS (GIBCO, BRL). Fifty μ l of cell lysis buffer (Promega, Madison, WI) is added to each well and the plates are shaken for 15 min in a Titer Plate Shaker (Lab Line Instrument, Inc.). Luciferase activity is measured using luciferase reagents from Promega.

- 33 -

c. Analysis of Results:

Each treatment consists of at least 4 replicates. Log transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. EC₅₀ or IC₅₀ values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear response analyses.

d. Reference Compounds:

Progesterone and trimegestone are reference progestins and RU486 is the reference antiprogestin. All reference compounds are run in full dose-response curves and the EC₅₀ or IC₅₀ values are calculated.

Table 1. Estimated EC₅₀, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three individual studies

Compound	Exp.	EC ₅₀	SE	95% CI	
		(nM)		lower	upper
Progesterone	1	0.616	0.026	0.509	0.746
	2	0.402	0.019	0.323	0.501
	3	0.486	0.028	0.371	0.637
Trimegestone	1	0.0075	0.0002	0.0066	0.0085
	2	0.0081	0.0003	0.0070	0.0094
	3	0.0067	0.0003	0.0055	0.0082

Table 2. Estimated IC₅₀, standard error (SE), and 95% confident interval (CI) for the antiprogestin, RU486 from three individual studies

Compound	Exp.	IC 50	SE	95% CI	
		(nM)		lower	upper
RU486	1	0.028	0.002	0.019	0.042
	2	0.037	0.002	0.029	0.048
	3	0.019	0.001	0.013	0.027

- 34 -

Progestational activity: Compounds that increase PRE-luciferase activity significantly ($p < 0.05$) compared to vehicle control are considered active.

Antiprogestational activity: Compounds that decrease 3 nM progesterone induced PRE-luciferase activity significantly ($p < 0.05$)

5 EC_{50} : Concentration of a compound that gives half-maximal increase PRE-luciferase activity (default-nM) with SE.

IC_{50} : Concentration of a compound that gives half-maximal decrease in 3 nM progesterone induced PRE-luciferase activity (default-nM) with SE.

3. T47D cell proliferation assay

10 The objective of this assay is the determination of progestational and antiprogestational potency by using a cell proliferation assay in T47D cells. A compound's effect on DNA synthesis in T47D cells is measured. The materials and methods used in this assay are as follows.

a. Growth medium: DMEM:F12 (1:1)
15 (GIBCO, BRL) supplemented with 10% (v/v) fetal bovine serum (not heat-inactivated), 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).

b. Treatment medium: Minimum Essential
Medium (MEM) (#51200-038 GIBCO, BRL) phenol red-free supplemented with 0.5%
20 charcoal stripped fetal bovine serum, 100U/ml penicillin, 200 mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).

c. Cell culture

Stock T47 D cells are maintained in growth medium. For BrdU incorporation
assay, cells are plated in 96-well plates (Falcon, Becton Dickinson Labware) at 10,000
25 cells/well in growth medium. After overnight incubation, the medium is changed to treatment medium and cells are cultured for an additional 24 hr before treatment. Stock compounds are dissolved in appropriate vehicle (100% ethanol or 50% ethanol/50% DMSO), subsequently diluted in treatment medium and added to the cells. Progestin and antiprogestin reference compounds are run in full dose-response

- 35 -

curves. The final concentration of vehicle is 0.1%. In control wells, cells receive vehicle only. Antiprogestins are tested in the presence of 0.03 nM trimegestone, the reference progestin agonist. Twenty-four hours after treatment, the medium is discarded and cells are labeled with 10 mM BrdU (Amersham Life Science, Arlington Heights, IL) in treatment medium for 4 hr.

d. Cell Proliferation Assay

At the end of BrdU labeling, the medium is removed and BrdU incorporation is measured using a cell proliferation ELISA kit (#RPN 250, Amersham Life Science) according to manufacturer's instructions. Briefly, cells are fixed in an ethanol containing fixative for 30 min, followed by incubation in a blocking buffer for 30 min to reduce background. Peroxidase-labeled anti-BrdU antibody is added to the wells and incubated for 60 min. The cells are rinsed three times with PBS and incubated with 3,3',5,5'-tetramethylbenzidine (TMB) substrate for 10-20 min depending upon the potency of tested compounds. Then 25 μ l of 1 M sulfuric acid is added to each well to stop color reaction and optical density is read in a plate reader at 450 nm within 5 min.

e. Analysis of Results:

Square root-transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. EC_{50} or IC_{50} values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear dose response analyses in both single dose and dose response studies.

f. Reference Compounds:

Trimegestone and medroxyprogesterone acetate (MPA) are reference progestins and RU486 is the reference antiprogestin. All reference compounds are run in full dose-response curves and the EC_{50} or IC_{50} values are calculated.

Table 3. Estimated EC₅₀, standard error (SE), and 95% confidence intervals (CI) for individual studies

	Compound	Exp	EC ₅₀ (nM)	SE	95% CI	
					lower	upper
5	Trimegestone	1	0.017	0.003	0.007	0.040
		2	0.014	0.001	0.011	0.017
		3	0.019	0.001	0.016	0.024
10	MPA	1	0.019	0.001	0.013	0.027
		2	0.017	0.001	0.011	0.024

Table 4. Estimated IC₅₀, standard error, and 95% confident interval for the antiprogesterin, RU486

	Compound	Exp	IC ₅₀ (nM)	SE	95% CI	
					lower	upper
15	RU486	1	0.011	0.001	0.008	0.014
		2	0.016	0.001	0.014	0.020
		3	0.018	0.001	0.014	0.022

- 20 EC₅₀: Concentration of a compound that gives half-maximal increase in BrdU incorporation with SE: IC₅₀: Concentration of a compound that gives half-maximal decrease in 0.1 trimegestone induced BrdU incorporation with SE

4. T47D cell alkaline phosphatase assay

- The purpose of this assay is to identify progestins or antiprogestins by
 25 determining a compound's effect on alkaline phosphatase activity in T47D cells. The materials and methods used in this assay are as follows.

a. Culture medium: DMEM:F12 (1:1) (GIBCO, BRL) supplemented with 5% (v/v) charcoal stripped fetal bovine serum (not heat-inactivated), 100U/ml penicillin, 100 µg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).

- 37 -

b. Alkaline phosphatase assay buffer:

I. 0.1 M Tris-HCl, pH 9.8, containing 0.2% Triton X-100

II. 0.1 M Tris-HCl, pH 9.8 containing 4 mM p-nitrophenyl phosphate (Sigma).

5

c. Cell Culture and Treatment:

Frozen T47D cells were thawed in a 37°C water bath and diluted to 280,000 cells/ml in culture medium. To each well in a 96-well plate (Falcon, Becton Dickinson Labware), 180 µl of diluted cell suspension was added. Twenty µl of reference or test compounds diluted in the culture medium was then added to each well. When testing for progestin antagonist activity, reference antiprogesterins or test compounds were added in the presence of 1 nM progesterone. The cells were incubated at 37°C in a 5% CO₂/humidified atmosphere for 24 hr.

10

d. Alkaline Phosphatase Enzyme Assay:

At the end of treatment, the medium was removed from the plate and fifty µl of assay buffer I was added to each well. The plates were shaken in a titer plate shaker for 15 min. Then 150 µl of assay buffer II was added to each well. Optical density measurements were taken at 5 min intervals for 30 min at a test wavelength of 405 nM.

15

e. Analysis of Results: Analysis of dose-response data

For reference and test compounds, a dose response curve is generated for dose (X-axis) vs. the rate of enzyme reaction (slope) (Y-axis). Square root-transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. EC₅₀ or IC₅₀ values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear dose response analyses in both single dose and dose response studies.

20

25

f. Reference Compounds:

Progesterone and trimegestone are reference progestins and RU486 is the reference antiprogesterin. All reference compounds are run in full dose response curves and the EC₅₀ or IC₅₀ values are calculated.

5

Table 5. Estimated EC₅₀, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three independent experiments

Compound	Exp.	EC ₅₀ (nM)	SE	95% CI	
				lower	upper
Progesterone	1	0.839	0.030	0.706	0.996
	2	0.639	0.006	0.611	0.669
	3	1.286	0.029	1.158	1.429
Trimegestone	1	0.084	0.002	0.076	0.091
	2	0.076	0.001	0.072	0.080
	3	0.160	0.004	0.141	0.181

Table 6. Estimated IC₅₀, standard error, and 95% confident interval for the reference antiprogesterin RU486 from three independent experiments

Compound	Exp	IC ₅₀ (nM)	SE	95% CI	
				lower	upper
RU486	1	0.103	0.002	0.092	0.115
	2	0.120	0.001	0.115	0.126
	3	0.094	0.007	0.066	0.134

B. In-vivo Biology

The primary in-vivo assay is the rat decidualization model, which may be used to determine progestational effects of both agonists and antagonists. The secondary in-vivo assay is the rat ovulation inhibition model, which is under development, and hence the protocol is un-available.

- 39 -

1. Rat decidualization assay The objective of this procedure is used to evaluate the effect of progestins and antiprogestins on rat uterine decidualization and compare the relative potencies of various test compounds. The materials and methods used in this assay are as follows.

5 a. Methods: Test compounds are dissolved in 100% ethanol and mixed with corn oil (vehicle). Stock solutions of the test compounds in oil (Mazola™) are then prepared by heating (~80 °C) the mixture to evaporate ethanol. Test compounds are subsequently diluted with 100% corn oil or 10% ethanol in corn oil prior to the treatment of animals. No difference in decidual response was found
10 when these two vehicles were compared.

b. Animals (RACUC protocol #5002)

Ovariectomized mature female Sprague-Dawley rats (~60-day old and 230g) are obtained from Taconic (Taconic Farms, NY) following surgery. Ovariectomy is performed at least 10 days prior to treatment to reduce circulating sex steroids.
15 Animals are housed under 12 hr light/dark cycle and given standard rat chow and water ad libitum.

c. Treatment

Rats are weighed and randomly assigned to groups of 4 or 5 before treatment. Test compounds in 0.2 ml vehicle are administered by subcutaneous
20 injection in the nape of the neck or by gavage using 0.5 ml. The animals are treated once daily for seven days. For testing antiprogestins, animals are given the test compounds and a EC50 dose of progesterone (5.6 mg/kg) during the first three days of treatment. Following decidual stimulation, animals continue to receive progesterone until necropsy four days later.

25 d. Dosing

Doses are prepared based upon mg/kg mean group body weight. In all studies, a control group receiving vehicle is included. Determination of dose-response curves is carried out using doses with half log increases (e.g. 0.1, 0.3, 1.0, 3.0 mg/kg...).

- 40 -

e. Decidual induction

Approximately 24 hr after the third injection, decidualization is induced in one of the uterine horns by scratching the antimesometrial luminal epithelium with a blunt 21 G needle. The contralateral horn is not scratched and serves as an unstimulated control. Approximately 24 hr following the final treatment, rats are sacrificed by CO₂ asphyxiation and body weight measured. Uteri are removed and trimmed of fat. Decidualized (D-horn) and control (C-horn) uterine horns are weighed separately.

f. Analysis of Results:

The increase in weight of the decidualized uterine horn is calculated by D-horn/C-horn and logarithmic transformation is used to maximize normality and homogeneity of variance. The Huber M-estimator is used to down weight the outlying transformed observations for both dose-response curve fitting and one-way analysis of variance. JMP software (SAS Institute, Inc.) is used for both one-way ANOVA and non-linear dose-response analyses.

g. Reference Compounds:

All progestin reference compounds were run in full dose-response curves and the EC₅₀ for uterine wet weight were calculated.

Table 7. Estimated EC₅₀, standard error (SE), and 95% confidence intervals for individual studies

Compound	Exp	EC ₅₀		95% CI	
		(mg/kg, s.c.)	SE	lower	upper
Progesterone	1	5.50	0.77	4.21	7.20
	2	6.21	1.12	4.41	8.76
3-Ketodesogestrel	1	0.11	0.02	0.07	0.16
	2	0.10	0.05	0.11	0.25
	3	0.06	0.03	0.03	0.14

- 41 -

5	Levonorgestrel	1	0.08	0.03	0.04	0.16
		2	0.12	0.02	0.09	0.17
		3	0.09	0.02	0.06	0.13
		4	0.09	0.02	0.06	0.14
5	MPA	1	0.42	0.03	0.29	0.60
		2	0.39	0.05	0.22	0.67
		3	0.39	0.04	0.25	0.61

10

Table 8. Estimated average EC₅₀, standard error, and 95% confidence intervals for dose-response curves of 3 reference compounds

		<u>EC₅₀</u>		<u>95% CI</u>	
		(mg/kg, s.c.)	SE	lower	upper
15	Progesterone	5.62	0.62	4.55	7.00
	3-Ketodesogestrel	0.10	0.02	0.07	0.14
	Levonorgestrel	0.10	0.01	0.08	0.12

Table 9. Estimated IC₅₀, standard error, and 95% confident interval for the antiprogestin, RU 486

		<u>IC₅₀</u>		<u>95% CI</u>	
		Exp. (mg/kg, p.o.)	SE	lower	upper
25	RU 486	1	0.21	0.05	0.96
		2	0.14	0.02	0.08 0.27

Concentration: Compound concentration in assay(default-mg/kg body weight)
 Route of administration: Route the compound is administered to the animals
 Body weight: Mean total animal body weight (default-kg)
 D-horn: Wet weight of decidualized uterine horn (default-mg)

30

- 42 -

C-horn: Wet weight of control uterine horn (default-mg)

Decidual response: $[(D-C)/C] \times 100\%$

Progestational activity: Compounds that induce decidualization significantly ($p < 0.05$) compared to vehicle control are considered active


5 Antiprogestational activity: Compounds that decrease EC_{50} progesterone induced decidualization significantly ($p < 0.05$)

EC_{50} for uterine weight: Concentration of compound that gives half-maximal increase in decidual response (default-mg/kg)

10 IC_{50} for uterine weight: Concentration of compound that gives half-maximal decrease in EC_{50} progesterone induced decidual response (default-mg/kg)

15 All publications cited in this specification are incorporated herein by reference herein. While the invention has been described with reference to a particularly preferred embodiment, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims.

- 43 -

What is Claimed:

wherein:

A, B and D are N or CH, with the proviso that A, B and D can not all be CH;

R^1 and R^2 are independent substituents selected from H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_2 to C_6 alkenyl, substituted C_2 to C_6 alkenyl, C_2 to C_6 alkynyl, substituted C_2 to C_6 alkynyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A , $NR^B COR^A$;

or R^1 and R^2 are fused to form a spirocyclic ring selected from a), b) or c), each spirocyclic ring optionally substituted by from 1 to 3 C_1 - C_3 alkyl groups:

- a) a 3 to 8 membered spirocyclic alkyl ring;
- b) a 3 to 8 membered spirocyclic alkenyl ring; or
- c) an optionally substituted 3 to 8 membered heterocyclic ring containing one to three heteroatoms from the group including O, S and N; the spirocyclic rings of a), b) and c) being optionally substituted by from 1 to 4 groups selected from fluorine, C_1 to C_6 alkyl, C_1 to C_6 alkoxy, C_1 to C_6 thioalkyl, $-CF_3$, $-OH$, $-CN$, NH_2 , $-NH(C_1$ to C_6 alkyl), or $-N(C_1$ to C_6 alkyl) $_2$;

R^A is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;


- 44 -

R^B is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

R^3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_6 alkenyl, substituted C_1 to C_6 alkenyl, or COR^C ;

R^C is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^4 is a trisubstituted benzene ring containing the substituents X, Y and Z as shown below:



X is taken from the group including halogen, CN, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 thioalkoxy, substituted C_1 to C_3 thioalkoxy, amino, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5 or 6 membered heterocyclic ring containing 1 to 3 heteroatoms, COR^D , $OCOR^D$, or $NR^E COR^D$;

R^D is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^E is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

- 45 -

Y and Z are independent substituents taken from the group including H, halogen, CN, NO₂, C₁ to C₃ alkoxy, C₁ to C₃ alkyl, or C₁ to C₃ thioalkoxy;

or

R⁴ is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO₂ or NR⁵ and containing one or two independent substituents from the group including H, halogen, CN, NO₂ and C₁ to C₃ alkyl, C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, COR^F, or NR^GCOR^F;

R^F is H, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, aryl, substituted aryl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, or substituted C₁ to C₃ aminoalkyl;

R^G is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl;

R⁵ is H or C₁ to C₃ alkyl;

Q is O, S, NR⁶, or CR⁷R⁸;


R₆ is from the group including CN, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO₂CF₃;

R⁷ and R⁸ are independent substituents from the group including H, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO₂, or CN CO₂R⁹;

R⁹ is C₁ to C₃ alkyl;


- 46 -

or CR⁷R⁸ form a six membered ring of the structure below:



W is O or a chemical bond;
or a pharmaceutically acceptable salt thereof.

2 A compound of Claim 1 having the formula:



I

wherein:

A, B and D are N or CH, with the proviso that A, B and D can not all be CH;

R¹ is H, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A, or NR^BCOR^A;

R² is H, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₂ to C₆ alkenyl, substituted C₂ to C₆ alkenyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, COR^A, or NR^BCOR^A;

or

- 47 -

R^1 and R^2 are fused to form the optionally substituted 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings described above;


R^A is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^B is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

R^3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_6 alkenyl, substituted C_1 to C_6 alkenyl, or COR^C ;

R^C is H, C_1 to C_4 alkyl, substituted C_1 to C_4 alkyl, aryl, substituted aryl, C_1 to C_4 alkoxy, substituted C_1 to C_4 alkoxy, C_1 to C_4 aminoalkyl, or substituted C_1 to C_4 aminoalkyl;

R^4 is a trisubstituted benzene ring containing the substituents X, Y and Z as shown below:



X is selected from halogen, CN, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 thioalkoxy, substituted C_1 to C_3 thioalkoxy, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, NO_2 , C_1 to C_3 perfluoroalkyl, a 5 membered heterocyclic ring containing 1 to 3 heteroatoms, COR^D , $OCOR^D$, or $NR^E COR^D$.

- 48 -

R^D is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^E is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;

Y and Z are independent substituents selected from H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_3 alkyl, or C_1 to C_3 thioalkoxy;

or

R^5 is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO_2 or NR^5 and containing one or two independent substituents from the group including H, halogen, CN, NO_2 and C_1 to C_3 alkyl, or C_1 to C_3 alkoxy;

R^5 is H or C_1 to C_3 alkyl;

Q is O, S, NR^6 , or CR^7R^8 ;


R_6 is selected from CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO_2CF_3 ;

R^7 and R^8 are independent substituents selected from H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , or CN CO_2R^9 ;

R^9 is C_1 to C_3 alkyl;

or CR^7R^8 form a six membered ring of the structure below:


- 49 -



W is O or a chemical bond;

or a pharmaceutically acceptable salt thereof.

3. A compound of Claim 1 of the formula:



I

wherein:

A, B and D are N or CH, with the proviso that A, B and D cannot all be CH;

$R^1 = R^2$ and are selected from the group of C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, or spirocyclic alkyl constructed by fusing R^1 and R^2 to form a 3 to 6 membered spirocyclic ring;


R^3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, or COR^C ;

R^C is H, C_1 to C_4 alkyl, or C_1 to C_4 alkoxy;

R^4 is selected from a), b) or c):

- 50 -

- a) R^4 is a benzene ring of the formula:




X is selected from the group of halogen, CN, C_1 to C_3 alkoxy, C_1 to C_3 alkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C_1 to C_3 thioalkoxy;

Y is a substituent on the 4' or 5' position from the group including H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_4 alkyl, or C_1 to C_3 thioalkoxy;

or

- b) R^4 is a five membered ring of the structure:



U is O, S, or NR^5 ;

R^5 is H, or C_1 to C_3 alkyl, or C_1 to C_4 CO_2 alkyl;


X' is selected from halogen, CN, NO_2 , C_1 to C_3 alkyl, or C_1 to C_3 alkoxy;

Y' is selected from H and C_1 to C_4 alkyl;

or

- c) R^4 is a six membered ring of the structure:

- 51 -



X^1 is N or CX^2 ;

X^2 is halogen, CN or NO_2 ;


Q is O, S, NR^6 , or CR^7R^8 ;

R_6 is selected from CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO_2CF_3 ;

R^7 and R^8 are independent substituents selected from H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , CN, or CO_2R^9 ;

R^9 is C_1 to C_3 alkyl;


or CR^7R^8 form a six membered ring of the structure below:



or a pharmaceutically acceptable salt thereof.

- 52 -

4. A compound of Claim 1 of the formula:



I

wherein:


A, B and D are N or CH, with the proviso that A, B and D can not all be CH;

$R^1 = R^2$ and are selected from CH_3 and spirocyclic alkyl constructed by fusing R^1 and R^2 to form a 6 membered spirocyclic ring;

R^3 is H, OH, NH_2 , CH_3 , substituted methyl, or COR^C ;

R^C is H, C_1 to C_3 alkyl, or C_1 to C_4 alkoxy;

R^4 is a disubstituted benzene ring containing the substituents X and Y as shown below:



X is halogen, CN, methoxy, NO_2 , or 2-thiazole;

Y is a substituent on the 4' or 5' position selected from H or F;

- 53 -


Q is O, S, NR^6 , or CR^7R^8 ;

R_6 is CN, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO_2CF_3 ;

R^7 and R^8 are independent substituents selected from H, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_8 cycloalkyl, substituted C_3 to C_8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO_2 , or $\text{CN CO}_2\text{R}^9$;

R^9 is C_1 to C_3 alkyl;


or CR^7R^8 form a six membered ring of the structure:



W is O or a chemical bond;

or a pharmaceutically acceptable salt thereof.


5. A compound of Claim 4 wherein R^4 is the moiety:



or a pharmaceutically acceptable salt thereof.

- 54 -

6. A compound of Claim 1 of the formula:



I

wherein:


A, B and D are N or CH, with the proviso that A, B and D can not all be CH;

$R^1 = R^2$ and are selected from CH_3 and spirocyclic alkyl constructed by fusing R^1 and R^2 to form a 6 membered spirocyclic ring;

R^3 is H, OH, NH_2 , CH_3 , substituted methyl, or COR^C ;

R^C is H, C_1 to C_3 alkyl, or C_1 to C_4 alkoxy;

R^4 is a five membered ring of the structure:



U is O, S, or NH;

X' is halogen, CN, or NO_2 ;

Y' is H or C_1 to C_4 alkyl;

- 55 -


Q is O, S, NR⁶, or CR⁷R⁸;

R₆ is CN, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO₂CF₃;

R⁷ and R⁸ are independent substituents selected from H, C₁ to C₆ alkyl, substituted C₁ to C₆ alkyl, C₃ to C₈ cycloalkyl, substituted C₃ to C₈ cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO₂, or CN CO₂R⁹;


R⁹ is C₁ to C₃ alkyl;

or CR⁷R⁸ form a six membered ring of the structure:



W is O or a chemical bond;
or a pharmaceutically acceptable salt thereof.

7. A compound of Claim 6 wherein R⁴ is a moiety selected from:



and Y' is selected from H or C₁ to C₄ alkyl; or a pharmaceutically acceptable salt thereof.

- 56 -

8. A compound of Claim 1 which is 6-(3-Chloro-phenyl)-4,4-dimethyl-1,4-dihydro-3-oxa-1,8-diaza-naphthalene-2-one or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Claim 1 and a pharmaceutically effective carrier or excipient.
10. A method of inducing contraception in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.
11. A method of treatment or prevention of benign or malignant neoplastic disease in a mammal, the method comprising administering to a mammal in need thereof a compound of Claim 1 wherein Q is oxygen, or a pharmaceutically acceptable salt thereof.
12. The method of Claim 9 wherein the benign or malignant neoplastic disease is selected from the group of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, meningioma or other hormone-dependent tumors.
13. A method of treatment or prevention in a mammal of carcinomas or adenocarcinomas of the endometrium, ovary, breast, colon, or prostate, the method comprising administering to a mammal in need thereof a compound of Claim 1 wherein Q is S, NR⁶, or CR⁷R⁸, or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/11836

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D498/04 A61K31/535 A61P15/18 A61P35/00
 //(C07D498/04,265:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 874 430 A (CHRIST DAVID DONALD ET AL) 23 February 1999 (1999-02-23) cited in the application column 12, line 28 -column 15, line 63; example 1	1-13
A	SINGH B ET AL: "NOVEL CAMP PDE III INHIBITORS: IMIDAZO'4,5-b!PYRIDIN-2-ONES AND THIAZOLO'4,5-b!PYRIDIN-2-ONES AND THEIR ANALOGS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 37, no. 2, 1994, pages 248-254, XP002146827 ISSN: 0022-2623 examples 43,54	1-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

7 September 2000

Date of mailing of the international search report

11.0.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Härtinger, S

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 00/11836

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>FOREST M.-C. ET AL: "A NOVEL CLASS OF CARDIOTONIC AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-SUBSTITUTED 3,6-DIHYDROTHIAZIN-2-ONES WITH CYCLIC AMP PHOSPHODIESTERASE INHIBITING AND MYOFIBRILLAR CALCIUM SENSITIZING PROPERTIES"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 35, no. 1, 1992, pages 163-172, XP002146828 ISSN: 0022-2623 examples 35, 43</p> <p>---</p>	1-13
A	<p>KUMAR V ET AL: "SYNTHESIS OF 7-AZAINDOLE AND 7-AZAOXINDOLE DERIVATIVES THROUGH A PALLADIUM-CATALYZED CROSS-COUPLED REACTION"</p> <p>JOURNAL OF ORGANIC CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY, EASTON, vol. 57, no. 25, 4 December 1992 (1992-12-04), pages 6995-6998, XP000578238 ISSN: 0022-3263 examples 3A, 3B</p> <p>---</p>	1-13
A	<p>US 5 688 810 A (ZHI LIN ET AL) 18 November 1997 (1997-11-18) *schemes 8 and 12* table 4</p> <p>---</p>	1-13
A	<p>US 4 822 794 A (SPADA ALFRED P ET AL) 18 April 1989 (1989-04-18) *formulae IVa, IVb and IVc* example 1</p> <p>---</p>	1-13
A	<p>CANONNE P ET AL: "SPIROCYCLIZATION OF 1-(o-AMINOPHENYL)CYCLOALKANOLS AND 1-(2'-AMINO-3'-PYRIDINYL)CYCLOALKANOLS"</p> <p>JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 26, 1989, pages 113-117, XP002146829 table 2</p> <p>---</p>	1-13
A	<p>TURCK A ET AL: "ON THE METALATION OF 3-SUBSTITUTED AND 3,6-DISUBSTITUTED PYRIDAZINES"</p> <p>TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 49, no. 3, 1993, pages 599-606, XP002146830 ISSN: 0040-4020 examples 10A, 11A</p> <p>-----</p>	1-13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/11836

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 11 to 13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/11836

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5874430	A	23-02-1999	NONE
US 5688810	A	18-11-1997	AU 717251 B 23-03-2000
		AU 4597796 A	10-07-1996
		BR 9510486 A	02-06-1998
		CA 2208347 A	27-06-1996
		CN 1175247 A	04-03-1998
		CZ 9701761 A	16-09-1998
		EP 0800519 A	15-10-1997
		JP 10510840 T	20-10-1998
		NO 972591 A	14-08-1997
		WO 9619458 A	27-06-1996
		US 6093821 A	25-07-2000
		HU 78117 A	29-11-1999
		US 5696130 A	09-12-1997
		US 5688808 A	18-11-1997
		US 5693646 A	02-12-1997
		US 5693647 A	02-12-1997
		US 5696127 A	09-12-1997
		US 5696133 A	09-12-1997
		US 5994544 A	30-11-1999
US 4822794	A	18-04-1989	AU 622861 B 30-04-1992
		AU 1725188 A	06-12-1988
		EP 0357675 A	14-03-1990
		JP 2503426 T	18-10-1990
		WO 8808705 A	17-11-1988
		US 4866074 A	12-09-1989
		US 5015638 A	14-05-1991